Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
Year: 2020
Type: article
Study design: Clinical Trial
Source: Leukemia
Authors: Joshua F. Zeidner, Hanna A. Knaus, Amer M. Zeidan, Amanda L. Blackford, Raul Montiel-Esparza, Hubert Hackl, Gabrielle T. Prince, Lukasz P. Gondek, Gabriel Ghiaur, Margaret M. Showel, Amy E. DeZern, Keith W. Pratz, B. Douglas Smith, Mark J. Levis, Steven Gore, Catherine C. Coombs, Matthew C. Foster, Howard Streicher, Judith E. Karp, Leo Luznik, Ivana Gojo
Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Medical University of Vienna, Yale Cancer Center, Innsbruck Medical University, Universität Innsbruck, National Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Health and Human Services, Leukemia and Lymphoma Society, Gabrielle's Angel Foundation for Cancer Research, American Society for Blood and Marrow Transplantation, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Advancing Translational Sciences
Awards: G2671550936, G3219430109, UNC Oncology K12, G4720334866, Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics, Hedgehog Signaling in the Progression of Myelodysplastic Syndromes, Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer, VICKtOrY Early Clinical Trials Consortium, The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies, Yale Clinical and Translational Science Award, The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network, Regional Oncology Research Center, Cancer Center Support Grant
OpenAlex ID: W2998293013